Bright Lisa 4
4 · INTERCEPT PHARMACEUTICALS, INC. · Filed Jan 27, 2020
Insider Transaction Report
Form 4
Bright Lisa
CCO & Corp Affairs Officer
Transactions
- Award
Common Stock
2020-01-23+4,800→ 22,614 total - Award
Option to Purchase Common Stock
2020-01-23+7,900→ 7,900 totalExercise: $99.66Exp: 2030-01-23→ Common Stock (7,900 underlying)
Footnotes (2)
- [F1]Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2020.
- [F2]The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2020.